Literature DB >> 25588866

Mesenchymal stem cells inhibit Th17 cells differentiation via IFN-γ-mediated SOCS3 activation.

Xingxia Liu1, Shaoda Ren, Xuebin Qu, Chaozhuo Ge, Kai Cheng, Robert Chun Hua Zhao.   

Abstract

Mesenchymal stem cells (MSCs) are immunoregulatory, and the administration of them has been shown to ameliorate inflammation caused by Th17 cells. However, the mechanisms that contribute to MSC regulation on Th17 cell development are unclear. Here, we found that MSCs could inhibit Th17 cell differentiation through the activation of suppressors of cytokine signaling 3 (SOCS3) when coculture of MSCs and CD4(+)CD25(low)CD44(low)CD62L(high) T cells. Further analysis demonstrated that the inhibitory action was mediated via interferon gamma (IFN-γ), which activated signal transducer and activator of transcription-1 (STAT1) to enhance the expression of SOCS3, leading to STAT3 inhibition. Moreover, stable and reciprocal changes in H3K4me3 and H3K27me3 at the promoters of STAT1, STAT3 and RORγt determined the fate of Th17 cells. These results demonstrate that MSCs may inhibit Th17 differentiation via IFN-γ that activates SOCS3 leading to immunomodulatory effects, suggesting a possible mechanism by which MSCs could act as a cellular approach to attenuate the clinical and pathological manifestations of some autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25588866     DOI: 10.1007/s12026-014-8612-2

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  45 in total

Review 1.  Suppressors of cytokine signaling and immunity.

Authors:  Masato Kubo; Toshikatsu Hanada; Akihiko Yoshimura
Journal:  Nat Immunol       Date:  2003-12       Impact factor: 25.606

Review 2.  Different bacterial pathogens, different strategies, yet the aim is the same: evasion of intestinal dendritic cell recognition.

Authors:  Sammy Bedoui; Andreas Kupz; Odilia L Wijburg; Anna K Walduck; Maria Rescigno; Richard A Strugnell
Journal:  J Immunol       Date:  2010-03-01       Impact factor: 5.422

Review 3.  The epigenetic face of systemic lupus erythematosus.

Authors:  Esteban Ballestar; Manel Esteller; Bruce C Richardson
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

4.  Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells.

Authors:  Zhenxing Guo; Cuiling Zheng; Zhenping Chen; Dongsheng Gu; Weiting Du; Jing Ge; Zhongchao Han; Renchi Yang
Journal:  Eur J Immunol       Date:  2009-10       Impact factor: 5.532

5.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

6.  Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells.

Authors:  Gang Wei; Lai Wei; Jinfang Zhu; Chongzhi Zang; Jane Hu-Li; Zhengju Yao; Kairong Cui; Yuka Kanno; Tae-Young Roh; Wendy T Watford; Dustin E Schones; Weiqun Peng; Hong-Wei Sun; William E Paul; John J O'Shea; Keji Zhao
Journal:  Immunity       Date:  2009-01-16       Impact factor: 31.745

7.  Overexpression of CNTF in Mesenchymal Stem Cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice.

Authors:  Zhengqi Lu; Xueqiang Hu; Cansheng Zhu; Dunjing Wang; Xueping Zheng; Quentin Liu
Journal:  J Neuroimmunol       Date:  2008-12-09       Impact factor: 3.478

8.  Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid.

Authors:  Daniel Mucida; Yunji Park; Gisen Kim; Olga Turovskaya; Iain Scott; Mitchell Kronenberg; Hilde Cheroutre
Journal:  Science       Date:  2007-06-14       Impact factor: 47.728

9.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

Authors:  Marc Veldhoen; Richard J Hocking; Christopher J Atkins; Richard M Locksley; Brigitta Stockinger
Journal:  Immunity       Date:  2006-02       Impact factor: 31.745

10.  Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis.

Authors:  Takeru Yoshimura; Koh-Hei Sonoda; Nobuyuki Ohguro; Yoshiyuki Ohsugi; Tatsuro Ishibashi; Daniel J Cua; Takashi Kobayashi; Hiroki Yoshida; Akihiko Yoshimura
Journal:  Rheumatology (Oxford)       Date:  2009-01-22       Impact factor: 7.580

View more
  20 in total

1.  Role of Suppressor of Cytokine Signaling 3 in the Immune Modulation of Mesenchymal Stromal Cells.

Authors:  Chen Yang; Chunquan Zheng; Hai Lin; Jing Li; Keqing Zhao
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

Review 2.  Current understanding of the immunosuppressive properties of mesenchymal stromal cells.

Authors:  Ligia Lins de Castro; Miquéias Lopes-Pacheco; Daniel Jay Weiss; Fernanda Ferreira Cruz; Patricia Rieken Macêdo Rocco
Journal:  J Mol Med (Berl)       Date:  2019-03-22       Impact factor: 4.599

Review 3.  Bivalent Regulation and Related Mechanisms of H3K4/27/9me3 in Stem Cells.

Authors:  Han Sun; Yin Wang; Ying Wang; Feng Ji; An Wang; Ming Yang; Xu He; Lisha Li
Journal:  Stem Cell Rev Rep       Date:  2021-08-21       Impact factor: 5.739

Review 4.  Modulation of Mesenchymal Stem Cells-Mediated Adaptive Immune Effectors' Repertoire in the Recovery of Systemic Lupus Erythematosus.

Authors:  Akram Hoseinzadeh; Zahra Rezaieyazdi; Jalil Tavakol Afshari; Ali Mahmoudi; Sahar Heydari; Reza Moradi; Seyed-Alireza Esmaeili; Mahmoud Mahmoudi
Journal:  Stem Cell Rev Rep       Date:  2022-10-22       Impact factor: 6.692

5.  Human umbilical cord derived mesenchymal stem cells promote interleukin-17 production from human peripheral blood mononuclear cells of healthy donors and systemic lupus erythematosus patients.

Authors:  S Ren; J Hu; Y Chen; T Yuan; H Hu; S Li
Journal:  Clin Exp Immunol       Date:  2015-12-16       Impact factor: 4.330

6.  Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling.

Authors:  Laixi Bi; Junqing Wu; Aifang Ye; Jianbo Wu; Kang Yu; Shenghui Zhang; Yixiang Han
Journal:  J Transl Med       Date:  2016-05-12       Impact factor: 5.531

7.  Th17 Pathway As a Target for Multipotent Stromal Cell Therapy in Dogs: Implications for Translational Research.

Authors:  A Kol; N J Walker; M Nordstrom; D L Borjesson
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

Review 8.  Role of Stem Cells in Pathophysiology and Therapy of Spondyloarthropathies-New Therapeutic Possibilities?

Authors:  Magdalena Krajewska-Włodarczyk; Agnieszka Owczarczyk-Saczonek; Waldemar Placek; Adam Osowski; Piotr Engelgardt; Joanna Wojtkiewicz
Journal:  Int J Mol Sci       Date:  2017-12-28       Impact factor: 5.923

Review 9.  Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.

Authors:  Juan Xiao; Rongbing Yang; Sangita Biswas; Xin Qin; Min Zhang; Wenbin Deng
Journal:  Int J Mol Sci       Date:  2015-04-24       Impact factor: 5.923

10.  Continuous time Bayesian networks identify Prdm1 as a negative regulator of TH17 cell differentiation in humans.

Authors:  Enzo Acerbi; Elena Viganò; Michael Poidinger; Alessandra Mortellaro; Teresa Zelante; Fabio Stella
Journal:  Sci Rep       Date:  2016-03-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.